Prelude Therapeutics (PRLD) Operating Expenses (2019 - 2026)

Prelude Therapeutics has reported Operating Expenses for 8 years, with the latest figure at $18.8 million in Q1 2026.

• Quarterly Operating Expenses fell 45.8% year-over-year to $18.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $100.9 million (down 31.38% YoY) and the FY2025 annual result came in at $116.7 million, down 20.45% from the prior year.
• Operating Expenses slipped to $18.8 million in Q1 2026 per PRLD's latest filing, from $23.0 million in the prior quarter.
• Over five years, Operating Expenses peaked at $37.8 million in Q4 2024 and troughed at $18.8 million in Q1 2026.
• A 5-year average of $31.6 million and a median of $32.4 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses surged 37.88% in 2022, then plunged 45.8% in 2026.
• Over 5 years, Operating Expenses stood at $33.4 million in 2022, then advanced by 11.96% to $37.4 million in 2023, then increased by 1.21% to $37.8 million in 2024, then tumbled by 39.24% to $23.0 million in 2025, then decreased by 18.41% to $18.8 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $18.8 million, $23.0 million, and $26.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.